scale average bioequivalence for parallel design [RSABE / ABEL]

posted by Mahmoud  – Jordan, 2022-06-15 14:33 (290 d 17:58 ago) – Posting: # 23059
Views: 1,010

Dear All
In the following paper

Statistical methodology for highly variable compounds: A novel design approach for the Ofatumumab Phase 2 bioequivalence study

Used scale average bioequivalence for parallel design

Is this method accepted by FDA and EMA


Edit: Category changed; see also this post #1[Helmut]

Complete thread:

UA Flag
 Admin contact
22,560 posts in 4,725 threads, 1,607 registered users;
13 visitors (0 registered, 13 guests [including 7 identified bots]).
Forum time: 08:32 CEST (Europe/Vienna)

No written law has ever been more binding than
unwritten custom supported by popular opinion.    Carrie Chapman Catt

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz